Trial · NCT02052648
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Frequency of Regimen-Limiting Toxicities (RLTs) in Phase 1 Subjects | Phase 1 Dose Level 1 | 0 | Participants | ||
| Frequency of Regimen-Limiting Toxicities (RLTs) in Phase 1 Subjects | Phase 1 Dose Level 2 | 0 | Participants | ||
| Frequency of Regimen-Limiting Toxicities (RLTs) in Phase 1 Subjects | Phase 1 Dose Level 3 | 0 | Participants | ||
| Phase 2: Number of Phase 1 Participants With Efficacy Outcomes | Phase 2 Cohort 2a | 18.6 | 95% Confidence Interval 10.4 to 28.8 | Percent | |
| Phase 2: Number of Phase 1 Participants With Efficacy Outcomes | Phase 2 Cohort 2b | 3.9 | 95% Confidence Interval 0.3 to 16.6 | Percent | |
| Phase 2: Number of Phase 1 Participants With Efficacy Outcomes | Phase 2 Cohort 2c | 22.9 | 95% Confidence Interval 10.5 to 38.3 | Percent | |
| Overall Response Rate for Phase 2 Participants | Phase 2 Cohort 2a | 5.2 | 95% Confidence Interval 1.4 to 12.8 | Percent | |
| Overall Response Rate for Phase 2 Participants | Phase 2 Cohort 2b | 0 | 95% Confidence Interval 0 to 12.3 | Percent | |
| Overall Response Rate for Phase 2 Participants | Phase 2 Cohort 2c | 7.7 | 95% Confidence Interval 1.6 to 20.9 | Percent | |
| Number of Participants With Adverse Events as a Measure of Safety and Tolerability | Phase 1 Dose Level 1 | 3 | Participants | ||
| Number of Participants With Adverse Events as a Measure of Safety and Tolerability | Phase 1 Dose Level 2 | 3 | Participants | ||
| Number of Participants With Adverse Events as a Measure of Safety and Tolerability | Phase 1 Dose Level 3 | 6 | Participants | ||
| Number of Participants With Adverse Events as a Measure of Safety and Tolerability | Phase 2 Cohort 2a | 72 | Participants | ||
| Number of Participants With Adverse Events as a Measure of Safety and Tolerability | Phase 2 Cohort 2b | 27 | Participants | ||
| Number of Participants With Adverse Events as a Measure of Safety and Tolerability | Phase 2 Cohort 2c | 39 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02052648/results